Screening for prostate cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ASIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ECHOGRAPHY; EUROPE; HEALTH CARE POLICY; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SOUTHEAST ASIA; SOUTHERN EUROPE; UNITED STATES;

CARCINOMA; EARLY DETECTION OF CANCER; EFFICIENCY; HISTORY, 20TH CENTURY; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80053239666     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70160-5     Document Type: Article

References (39)

1. Globocan Available through www.clip.iarc.fr 2008
2. R Etzioni, A Tsodikov, A Mariotto et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19 2 2008 Mar 175 181
3. PH Gann, CH Henne kens, MX Stampfer A prospective evaluation of plasma prostate-specific antigen for the detection of prostatic cancer JAMA 273 4 1995 Jan 25 289 294
4. G Draisma, R Boer, SJ Otto et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized study of Screening for Prostate Cancer JNatl Cancer Inst 95 12 2003 Jun 18 868 878 (Pubitemid 36833878)
5. C Bouchardy, G Fioretta, E Rapiti et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries IntJ Cancer 123 2 2008 Jul 15 421 429 (Pubitemid 351842029)
6. R Kvale, A Auvinen, HO Adami et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries JNati Cancer Inst 99 24 2007 Dec 19 1881 1887 (Pubitemid 351767195)
7. EA Platz, MF Leitzmann, K Visvanathan et al. Statin drugs and risk of advanced prostate cancer J Nati Cancer Inst 98 24 2006 Dec20 1819 1825 (Pubitemid 46017933)
8. HB Carter, JD Pearson, EJ Metter et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267 16 1992 Apr 22-29 2215 2220
9. IM Thompson, DK Pauler, PJ Goodman et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per millilitre N Eng J Med 350 22 2004 May 27 2239 2246
10. FH Schröder, J Hugosson, MJ Roobol for the ERSPC investigators Screening and pro state-cancer mortality in a randomized European study N Engl J Med 360 13 2009 Mar26 1320 1328
11. PC Albertsen, JA Hanley, DF Gleason, MJ Barry Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 ll 1998 Sep 16 975 980 (Pubitemid 28445095)
12. PC Albertsen, JA Hanley, J Fine 2-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 17 2005 May 4 2095 2101 (Pubitemid 40617061)
13. JC Kimbrough Symposium on prostate cancer. II. Importance of early detection J Nati Med Assoc 47 3 1955 May 149 152
14. Cancer Research UK www.cancerresearchuk.org
15. C Gosselaar, MJ Roobol, RC van den Bergh, T Wolters, FH Schröder Digital rectal examination and the diagnosis of prostate cancer - a study based on 8 years and three screenings within the European Randomized study of Screening for Prostate Cancer (ERSPC), Rotterdam Eur Urol 55 l 2009 Jan 139 146
16. C Gosselaar, MJ Roobol, S Roemeling, FH Schröder The role of digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam Eur Urol 54 3 2008 Sep 581 588
17. C Gosselaar, MJ Roobol, S Roemeling, T Wolters, GJ van Leenders, FH Schröder The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer BJU Int 101 6 2008 Mar 685 690 (Pubitemid 351269996)
18. PJ Van Leeuwen, D Connolly, TL Tammela et al. Balancing the harms and benefits of early detection of prostate cancer Cancer 116 20 2010 Oct 15 4857 4865
19. IM Thompson, DP Ankerst, C Chi et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower JAMA 294 l 2005 Jul 6 66 70 (Pubitemid 41002840)
20. MJ Roobol, IW van der Cruijsen, FH Schröder No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/ml or greater (ERSPC, Rotterdam) Urology 63 5 2004 May 892 897 (Pubitemid 38596673)
21. H Lilja, D Ulmert, T Björk et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 4 2007 Feb 1 431 436 (Pubitemid 350002992)
22. J Fang, EJ Metter, P Landis, DW Chan, CH Morrell, HB Carter Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Ageing Urology 58 3 2001 Sep 411 416 (Pubitemid 32816360)
23. NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer, 2011 - available through www.nccn.org.
24. HJ De Koning, MK Liem, CA Baan, R Boer, FH Schröder, FE Alexander, on behalf of ERSPC Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized study of Screening for Prostate Cancer (ERSPC) trial Int J Cancer 98 2002 268 273 (Pubitemid 34150812)
25. PJ Van Leeuwen, X Zhu, M Bul, FH Schröder, MJ Roobol, CH Bangma Prostaatkankerincidentie en mortaliteit de körnende jaren - zijn we voorbereid? NTGV 6 October 2010 162
26. HJ De Koning, J Blom, JW Merkelbach et al. Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 Suppl 2 2003 71 78 (Pubitemid 38091145)
27. MJ Roobol, M Kerkhof, FH Schröder et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomized study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 4 2009 Oct 584 591
28. GL Andriole, ED Crawford, RL Grubb 3rd PLCO Project Team Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 13 2009 Mar 26 1310 1319
29. J Hugosson, S Carlsson, G Aus et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 8 2010 Aug 725 732
30. M Zappa, S Ciatto, R Bonardi, A Mazzotta Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study Ann Oncol 9 12 1998 Dec 1297 1300 (Pubitemid 29045568)
31. R Etzioni, DF Penson, JM Legier et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Nati Cancer Inst 94 13 2002 Jul 3 981 990 (Pubitemid 34814727)
32. MJ Roobol, FH Schröder, ED Crawford et al. A framework for the identification of men at increased risk for prostate cancer J Urol 182 5 2009 Nov 2112 2120
33. V Cavadas, L Osorio, F Sabell, F Teves, F Branco, M Silva-Ramos Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort Eur Urol 58 4 2010 Oct 551 558
34. A Sciarra, V Panebianco, M Ciccariello et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy Clin Cancer Res 16 6 2010 Mar 15 1875 1883
35. T Hambrock, DM Somford, C Hoeks et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen J Urol 183 2 2010 Feb 520 527
36. MJ Roobol, FH Schröder, P van Leeuwen et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 40 2010 Oct 475 481
37. MJ Roobol, FH Schröder, GL van Leenders et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100) Eur Urol 58 6 2010 Dec 893 899
38. BE Helgeson, SA Tomlins, N Shah et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer Cancer Res 68 l 2008 Jan 1 73 80 (Pubitemid 351380107)
39. MJ Roobol, EW Steyerberg, R Kranse et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 l 2010 Jan 79 85